Rejuvel Bio-Sciences, Inc.
Other OTCTotal Valuation
Rejuvel Bio-Sciences, Inc. carries a market capitalization of 117,765.00, placing it among publicly traded companies globally. Its enterprise value stands at 15.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 117,765.00 |
| Enterprise Value | 15.54M |
Share Statistics
Rejuvel Bio-Sciences, Inc. currently has 50.90M shares outstanding.
| Shares Outstanding | 50.90M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Rejuvel Bio-Sciences, Inc. trades at a trailing price-to-earnings ratio of 30.68. The price-to-sales ratio is 81.01, and the price-to-book ratio stands at -4.59.
| PE Ratio | 30.68 |
| PS Ratio | 81.01 |
| PB Ratio | -4.59 |
| P/TBV Ratio | -9.56 |
| P/FCF Ratio | -24.34 |
| P/OCF Ratio | -24.34 |
Enterprise Valuation
| EV / Sales | 82.94 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Rejuvel Bio-Sciences, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -23.00, indicating conservative leverage, while an interest coverage ratio of -5.25 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.05 |
| Quick Ratio | 0.00 |
| Debt / Equity | -23.00 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | -5.25 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -439.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 10.16 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.49 |
Stock Price Statistics
Rejuvel Bio-Sciences, Inc.'s stock has gained approximately 900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Rejuvel Bio-Sciences, Inc. generated 187,328.00 in revenue and converted that into -1.05M in net income, yielding earnings per share of -0.02. EBITDA reached -1.25M, while operating income came in at -1.26M.
| Revenue | 187,328.00 |
| Gross Profit | 88,807.00 |
| Operating Income | -1.26M |
| Pretax Income | -1.05M |
| Net Income | -1.05M |
| EBITDA | -1.25M |
| EBIT | -1.26M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Rejuvel Bio-Sciences, Inc. holds 877.00 in cash and equivalents against 361,655.00 in total debt, resulting in a net debt position of 360,778.00. Total book value stands at -3.31M, with working capital of -1.61M providing operational flexibility.
| Cash & Cash Equivalents | 877.00 |
| Total Debt | 361,655.00 |
| Net Debt | 360,778.00 |
| Equity (Book Value) | -3.31M |
| Book Value Per Share | -0.07 |
| Working Capital | -1.61M |
Cash Flow
Rejuvel Bio-Sciences, Inc. produced -623,519.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -623,519.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -623,519.00 |
| FCF Per Share | -0.01 |
Margins
Rejuvel Bio-Sciences, Inc. operates with a gross margin of 47.41, reflecting its pricing power and cost economics. The operating margin of -672.70 and net profit margin of -561.59 provide insight into operational efficiency.
| Gross Margin | 47.41 |
| Operating Margin | -672.70 |
| Pretax Margin | -561.59 |
| Profit Margin | -561.59 |
| EBITDA Margin | -668.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.98 |
| FCF Yield | -4.11 |
Scores
Rejuvel Bio-Sciences, Inc. posts an Altman Z-Score of -82.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -82.87 |